RECENT ADVANCES IN THE NEUROPROTECTIVE EFFECTS OF TRADITIONAL CHINESE MEDICINE: FOCUS ON ACTIVE INGREDIENTS AND MECHANISMS OF ACTION IN ALZHEIMER’S DISEASE
Keywords:
Alzheimer's disease, Traditional Chinese Medicine, Active ingredient, Mechanism of action, NeuroprotectionAbstract
Alzheimer's disease (AD) is a senile brain disease characterized by insidious onset and neurodegenerative pathology. According to reports from the World Health Organization, the global population of individuals affected by AD exceeds 55 million, with a new case occurring approximately every three seconds. This number is projected to exceed 150 million by the year 2050. Given the unclear pathogenesis of AD, there are currently no available etiological treatments. Traditional Chinese Medicine (TCM) is known for its multi-target therapeutic approach, which provides several advantages, including a variety of treatment methods, minimal side effects, and the capacity to coordinate effects across multiple targets and pathways. This makes TCM particularly significant for research focused on the prevention and treatment of AD. This paper utilizes TCM as a foundation to review recent research findings regarding its treatment of AD, including ganolearins A–D, ulmoidol (30), Ganoderma lucidum polysaccharide, Ganoderma sinense crude polysaccharide and so on . It identifies newly discovered active ingredients and treatment methods, with the aim of providing a theoretical basis for TCM approaches to AD and serving as a reference for drug development.References
[1] Cummings J. The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, 15(1): 172–178.
[2] Wu C, Ma D, Chen Y. Association of pulse pressure difference and diabetes mellitus in Chinese people: A cohort study.International Journal of General Medicine, 2021, 14: 6601-6608.
[3] Kamila P, Kar K, Chowdhury S, et al. Effect of neuroinflammation on the progression of Alzheimer’s disease and its significant ramifications for novel anti-inflammatory treatments. IBRO Neuroscience Reports, 2025, 18: 771-82.
[4] Miao Qi, Zhu Renyan, Li Niannian, et al. Progress in traditional Chinese medicine treatment of Alzheimer's Disease. Journal of Shaanxi University of Chinese Medicine, 2024, 47(1): 139-42.
[5] Zhang Tao, Zhao Lei, Zhan Rui, et al. Novel mechanisms of some traditional chinese medicine for the therapy of neurocognitive disorders. Progress In Biochemistry and Biophysics, 2020, 47(8): 729-742.
[6] Erli Fei , Yun Gu . Progress in the prevention and treatment of Alzheimer's disease with traditional Chinese medicine. Chinese Journal of Alzheimer's Disease and Related Disorders, 2025, 8(1): 67-72.
[7] Yuan Fang, Wang Gang. Progress in pharmacotherapy for Alzheimer's disease. Acta Academiae Medicinae Sinicae, 2024, 41(5): 702-708.
[8] Rafii M S, Aisen P S. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nature Reviews Neurology, 2025.
[9] Zhang He , Zheng Yan . β Amyloid Hypothesis in Alzheimer’s Disease: Pathogenesis, Prevention,and Management. Acta Academiae Medicinae Sinicae, 2019, 41(5): 702-708.
[10] Wang Guoqing. Advances in the study of Aβoligomers and Alzheimer's disease. Journal of Apoplexy and Nervous Diseases, 2023, 40(7): 579-83.
[11] Guo X, Li H, Yan C, et al. Molecular mechanism of substrate recognition and cleavage by human γ-secretase. Science, 2024, 384(6700): 1091-1095.
[12] Zheng Y F, Song Z Y, Lyu W C, et al. A review of research on A β 1-42 oligomers and Alzheimer's disease. Journal of Regional Anatomy and Operative Surgery, 2016(2): 142-144.
[13] Niu Z, Gui X, Feng S, et al. Aggregation mechanisms and molecular structures of Amyloid-β in Alzheimer's Disease. Chemistry, 2024: 1521-3765.
[14] Zhang P, Song C, Shi J, et al. Endothelium-specific endoglin triggers astrocyte reactivity via extracellular vesicles in a mouse model of Alzheimer's disease. Mol Neurodegener, 2025: 1750-1326.
[15] Azargoonjahromi A. The duality of amyloid-β: its role in normal and Alzheimer's disease states. Molecular Brain, 2024, 17(1).
[16] Zhang X, Hu J, Zhong L, et al. Quercetin stabilizes apolipoprotein E and reduces brain Aβ levels in amyloid model mice. Neuropharmacology, 2016, 108: 179-92.
[17] Benjamin Falcon , Wenjuan Zhang , Alexey G Murzin , et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature , 2018: 137–140.
[18] Zhang Xin, Zhu Tiantian, Wei Yuting, et al. Research progress on the mechanism of acupuncture intervention in Alzheimer's Disease via regulation of tau protein. Western Journal of Traditional Chinese Medicine, 2025, 38(3): 98-102.
[19] Gaikwad S, Senapati S, Haque M A, et al. Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies. Alzheimers Dement, 2024: 1552-5279.
[20] Arakhamia T, Lee CE, Carlomagno Y, et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell, 2021: 1097-4172.
[21] Wan H L, Hong X Y, Zhao Z H, et al. STAT3 ameliorates cognitive deficits by positively regulating the expression of NMDARs in a mouse model of FTDP-17. Signal Transduction and Targeted Therapy, Cell, 2020, 5(1): 295.
[22] Zeng F X, Zhao R Q, Wang B. Neuroprotective mechanism of exercise on Alzheimer’s Disease: Role of oxidative stress. Chinese Journal of Biochemistry and Molecular Biology, 2025, 41(5): 687-695.
[23] Wen L, Bi D, Shen Y. Complement-mediated synapse loss in Alzheimer's disease: mechanisms and involvement of risk factors. Trends in Neurosciences, 2024: 1878-108X.
[24] Puranik N, Song M. Oxidative stress and the role of immune cells in Alzheimer's Disease: therapeutic implications and future perspectives.CNS neurol disord drug targets, 2025: 1996-3181.
[25] Bodur O C, Hasanoglu Ozkan E, Colak O, et al. Preparation of acetylcholine biosensor for the diagnosis of